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Scope
T he Canadian Coalition for Seniors Mental Health (CCSMH) received a grant from the Substance Use and Addictions Program (SUAP) of Health Canada to create a set of four guidelines on the prevention, assessment, and management 
of substance use disorders among older adults for alcohol, BZRAs, cannabis, and opioids . The GRADE approach was 
utilized in the creation of these guidelines . The methodology can be found in a separate document at ccsmh .ca . 
An introduction to these guidelines which highlights issues of relevance to all four can also be found at ccsmh .ca .
These guidelines are not intended to provide a comprehensive guide on the use of these substances either by 
medical prescription or recreationally . Rather, the goal of this document is to provide useful guidance for clinicians 
on either preventing the development of BZRA use disorder or optimally assessing and treating older individuals 
who have developed such a disorder . It is important to note that clinicians will often wish to deprescribe BZRAs 
in older patients because of the risk of side effects, rather than because of evidence of a BZRA use disorder . 
Recommendations in the management section of this document, such as those dealing with gradual dose 
reduction, are also relevant to this group . Although our guidelines are described in four separate documents, 
multiple substance use is common . Clinicians are encouraged to utilize all of the guidelines when relevant .
Benzodiazepine Receptor Agonists: Drugs referred 
to as BZRAs act as allosteric modulators of gamma-
aminobutyric acid (GABA) activity by binding to 
inotropic benzodiazepine receptors at the GABA A 
receptor complex . BZRAs increase GABA binding and 
chloride ion channel opening, facilitating inhibitory 
activity . Some of these drugs have a benzodiazepine 
chemical structure (i .e ., alprazolam, bromazepam, 
chlordiazepoxide, clobazam, clonazepam, clorazepate, 
diazepam, flurazepam, lorazepam, midazolam, nitrazepam, 
oxazepam, temazepam, triazolam) while others, 
referred to as non-benzodiazepine receptor agonists, 
novel benzodiazepine receptor agonists, or z-drugs 
(i .e ., zolpidem, zopiclone), do not . We use the term BZRAs 
for both . Our recommendations deal with all BRZAs as 
they have similar benefits, side effects, and risks . These 
drugs have regulatory approval for the management 
of anxiety and panic disorders, short-term treatment 
of insomnia, seizures, alcohol withdrawal, sedation, 
and spasticity . They are also often used in an off-label 
manner (i .e ., any use of a drug beyond what Health 
Canada has reviewed and authorized to be marketed 
in Canada and as indicated on the product label), for 
example to treat anxious depression or the behavioural 
and psychological symptoms of dementia (BPSD), 
which are also described as responsive behaviours .
Definition of Key Terms 
5BZRA Use Disorder: This refers to a problematic pattern 
of BZRA use leading to clinically significant impairment or 
distress . According to DSM-5 criteria BZRA use disorder is 
manifested by at least two of the criteria below occurring 
within a 12-month period (American Psychiatric Association, 
2013) . It is important to note that among older adults, some 
of these criteria may be modified by the aging process 
or their social roles (e .g ., retirement from work), resulting 
in more subtle presentations (Kuerbis et al ., 2014) .
✚ The BZRA is taken in larger amounts or over a longer 
period of time than intended .
✚ Persistent desire or unsuccessful efforts to cut down or 
control BZRA use .
✚ A great deal of time is spent in activities to obtain BZRAs, 
use them, or recover from their effects .
✚ Craving, or a strong desire or urge to use a BZRA .
✚ Recurrent BZRA use resulting in a failure to fulfill major 
role obligations at work, school, or home .
✚ Continued use of the BZRA despite persistent or recurrent 
social or interpersonal problems caused or exacerbated 
by their effects .
✚ Important social, occupational, or recreational activities 
are given up or reduced because of BZRA use .
✚ Recurrent BZRA use in situations in which it is physically 
hazardous .
✚ Continued use of the BZRA despite knowledge 
of having a persistent or recurrent physical 
or psychological problem that is likely to have 
been caused or exacerbated by drug use .
✚ Tolerance as defined by either a need for markedly 
increased amounts of the BZRA to achieve intoxication or 
desired effect OR a markedly diminished effect with 
continued use of the same amount of the BZRA 
(note: criterion not considered to be met for an individual 
taking the drug under medical supervision) .
✚ Withdrawal as manifested by either characteristic 
withdrawal symptoms (i .e ., autonomic hyperactivity, hand 
tremor, insomnia, nausea or vomiting, transient sensory 
hallucinations or illusions, psychomotor agitation, anxiety, 
and/or seizures) OR the BZRA (or a closely related substance 
such as alcohol) is taken to relieve or avoid withdrawal 
symptoms .
Diagnosis
✚ 1 symptom or less, no diagnosis
✚ 2–3 symptoms, mild BZRA Use Disorder
✚ 4–5 symptoms, moderate BZRA Use Disorder
✚ 6 or more symptoms, severe BZRA Use Disorder
Remission
✚ 3–12 months with no criteria other than 
craving is considered early remission .
✚ More than 12 months is considered sustained remission .
6Summary of Recommendations and Grades
W e used the GRADE approach (Grading of Recommendations, Assessment, Development and Evaluation) as a method of grading the quality of evidence and the strength of recommendations . In following the GRADE process, the initial step was 
to grade the quality of available evidence supporting each recommendation . Subsequently, we identified the overall strength of 
the recommendation taking into account the quality of the evidence but also other factors such as the potential to do harm, the 
cost and feasibility . 
We have also developed a separate category for recommendations which are not primarily based on empirical evidence; but have 
agreement that they represent best clinical practice . Examples would include: optimal assessment processes and those related to 
education and/or policy . These recommendations have been categorized as “C” for consensus . We did not use the GRADE process 
for these recommendations . Other guideline groups have used a similar approach e .g . British Association for Psychopharmacology 
Guidelines (Lingford-Hughes et al ., 2012) . While such recommendations lack empirical evidence, we believe they are also useful 
and important .
***High quality evidence doesn’t necessarily imply strong recommendations, and strong recommendations can arise from low quality evidence.
Note: Meta analyses and Randomized Controlled Trials are considered high quality vs. Observational studies which are considered low quality
QUALITY OF EVIDENCE STRENGTH OF RECOMMENDATION 
The quality of evidence for each recommendation is determined 
through an examination of the following factors: (1) Study 
design and the quality of the studies that were included, (2) the 
directness of the evidence (generalizability or applicability) and 
(3) the confidence that patients will benefit from the treatment .
The strength of each recommendation is determined through an 
examination of the following factors:  
(1) The balance between benefits and undesirable effects/ risks, 
(2) uncertainty or variability of patient values and preferences 
and (3) the resources associated with management options .
GRADE
QUALITY OF EVIDENCE
STRENGTH OF RECOMMENDATION
HIGH Further research is unlikely to change confidence in the estimate of effect
MODERATE Further research is likely to have an important impact on the confidence in the estimate of effect and may 
change the estimate
LOW Further research is very likely to have an important impact on the confidence in the estimate of effect and is 
likely to change the estimate
STRONG Strong recommendations indicate high confidence that desirable consequences of the proposed course of 
action outweigh the undesirable consequences or vice versa .
WEAK Weak recommendations indicate that there is either a close balance between benefits and down sides 
(including adverse effects and burden of treatment), uncertainty regarding the magnitude of benefits and 
down sides, uncertainty or great variability in patients’ values and preferences, or that the cost or burden of the 
proposed intervention may not be justified .
(adapted from Guyatt et al, 2008)
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RECOMMENDATION #1: 
Long-term use of BZRAs (> 4 weeks) in older adults should be 
avoided for most indications because of their minimal efficacy and 
risk of harm. Older adults have increased sensitivity to BZRAs and 
decreased ability to metabolize some longer-acting agents, such as 
diazepam. All BZRAs increase the risk of cognitive impairment, 
delirium, falls, fractures, hospitalizations, and motor vehicle crashes. 
Alternative management strategies for insomnia, anxiety disorders, 
and the behavioural and psychological symptoms of dementia 
(BPSD) are recommended. [GRADE: Evidence: Moderate; Strength: 
Strong]
RECOMMENDATION #2: 
Appropriate first-line non-pharmacological options for the treatment 
of insomnia and anxiety disorders include cognitive behaviour 
therapies (CBTs) provided in various formats. [GRADE: Evidence: 
Moderate; Strength: Strong]
RECOMMENDATION #3: 
A BZRA should only be considered in the management of insomnia 
or anxiety after failing adequate trials of non-pharmacological 
interventions or safer pharmacological alternatives OR for short-
term bridging until more appropriate treatment becomes effective. 
[GRADE: Evidence: Moderate; Strength: Strong]
RECOMMENDATION #4: 
An assessment of risk for BZRA use disorder and other potential 
adverse effects from these agents should be done prior to 
prescribing a BZRA. [Consensus]
RECOMMENDATION #5: 
If a BZRA is being considered, the older adult should be informed of 
both the limited benefits and risks associated with use, as well as 
alternatives, prior to deciding on a management plan. [Consensus]
RECOMMENDATION #6: 
Initiating treatment with a BZRA should be a shared decision 
between the prescriber and the older adult (or their substitute 
decision-maker). There should be agreement and understanding on 
how the BZRA is to be used (including planned duration of no more 
than 2 to 4 weeks) and monitored. [Consensus]
RECOMMENDATION #7: 
Older adults who are receiving a BZRA should be:
a. Educated and provided the opportunity to discuss the ongoing 
risks of taking BZRAs. [GRADE: Evidence: Moderate; Strength: 
Strong] 
b. Encouraged to only take the BZRA for a short period of time 
(2 to 4 weeks or less) at the minimally effective dose. 
[GRADE: Evidence: Moderate; Strength: Strong] 
c. Monitored during the course of their prescription for evidence 
of treatment response and effectiveness, current and potential 
adverse effects, concordance with the treatment plan, and/or 
the development of a BZRA use disorder. [Consensus] 
d. Supported in stopping the drug, which may require a gradual 
reduction until discontinued. [GRADE: Evidence: Moderate; 
Strength: Strong] 
RECOMMENDATION #8: 
Health care providers and organizations should consider 
implementing interventions to decrease inappropriate use of BZRAs 
in their practice settings. These include medication reviews, 
prescribing feedback, audits and alerts, multidisciplinary case 
conferences, and brief educational sessions. Regulators, health 
authorities, and professional organizations should consult with 
clinical leaders and older adults to develop and implement policies 
that aim to minimize inappropriate use of BZRAs. [GRADE: Evidence: 
Low; Strength: Strong]
RECOMMENDATION #9: 
Health care institutions, including acute care hospitals and long-
term care facilities, should implement protocols that minimize new 
prescriptions for BZRAs because of the potential for harm and the 
risk of this leading to long-term use following discharge to the 
community or other transitions in care. [GRADE: Evidence: Low; 
Strength: Strong]
RECOMMENDATION #10: 
Health care practitioners, older adults, and their families should 
advocate for adequate access and funding of effective non-
pharmacological alternatives for the management of insomnia, 
anxiety disorders, and BPSD. [GRADE: Evidence: Low; Strength: 
Strong]
RECOMMENDATION #11: 
Clinicians should be aware that BZRAs are prescribed more 
frequently to women and the potential implicit bias that may lead to 
inappropriate use. [GRADE: Evidence: Low; Strength: Weak]
RECOMMENDATION #12: 
All older adults should be asked about current and past 
consumption of substances that might lead to substance use 
disorders, including BZRAs, during periodic health examinations, 
admissions to facilities or services, perioperative assessments, 
when considering the prescription of a BZRA, and at transitions 
in care. [Consensus]
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RECOMMENDATION #13: 
Health care practitioners should be aware of and vigilant to the 
symptoms and signs of substance use disorders, including BZRA use 
disorder. Particular attention should be paid to this possibility when 
assessing common conditions encountered in older adults, such as 
falls and cognitive impairment. [Consensus] 
RECOMMENDATION #14: 
Assessment of older adults suspected of having a BZRA use disorder 
should include indication, dose, duration, features indicative of BZRA 
use disorder, readiness to change, and presence of both medical and 
psychiatric comorbidities, including any other past or current 
substance use or misuse. [Consensus]
RECOMMENDATION #15:
a. Multiple substance use is common and should be considered 
and inquired about in all older adults with a BZRA use disorder. 
[GRADE: Evidence: Moderate; Strength: Strong] 
b. Health care practitioners should avoid prescribing BZRAs 
concurrently with opioids whenever possible. 
[GRADE: Evidence: Moderate; Strength: Strong] 
c. The combination of a BZRA with alcohol should be avoided. 
[GRADE: Evidence: Low; Strength: Weak] 
RECOMMENDATION #16: 
A person-centred, stepped-care approach to enable the gradual 
withdrawal and discontinuation of BZRAs should be used. Clinicians 
and patients should share in: a) planning and applying a gradual 
dose reduction scheme supported by appropriate education of the 
patient; b) identifying and optimizing alternatives to manage the 
underlying health issue(s) that initiated or perpetuated the use of 
BZRAs; c) developing strategies to minimize acute withdrawal and 
managing rebound symptoms as needed; and d) establishing a 
schedule of visits for reviewing progress. [GRADE: Evidence: 
Moderate; Strength: Strong]
RECOMMENDATION #17: 
Abrupt discontinuation of a BZRA after intermediate to long-term 
use (> 4 weeks) in individuals with BZRA use disorder should be 
avoided due to the risk of withdrawal symptoms, substance 
dependence reinforcement, rebound phenomena, and/or higher 
likelihood of relapse with resumption of BZRA use. 
[GRADE: Evidence: Moderate; Strength: Strong]
RECOMMENDATION #18: 
Management of acute BZRA withdrawal symptoms should be 
monitored carefully and can be guided by a validated tool [e.g. 
Benzodiazepine Withdrawal Symptom Questionnaire, Clinical 
Institute Withdrawal Assessment-Benzodiazepine (CIWA-B)] and 
managed with symptom-driven judicious use of an appropriate 
BZRA. [GRADE: Evidence: Low; Strength: Weak] 
RECOMMENDATION #19: 
Regimens involving multiple BZRAs should be simplified and 
converted to a single BZRA. [Consensus]
RECOMMENDATION #20: 
The routine switching of a short half-life BZRA with one having a 
long half-life to aid in withdrawing BZRAs is not generally 
recommended in older adults. Switching may have a role in certain 
situations, such as when withdrawal is being hindered by a limited 
number of available BZRA pill strengths or when alprazolam is the 
agent of dependence or misuse. [GRADE: Evidence: Moderate; 
Strength: Strong]
RECOMMENDATION #21: 
Psychological interventions such as CBT should be considered 
during efforts to withdraw BZRAs as they can improve the older 
adult’s experiences and increase the likelihood of stopping the BZRA. 
[GRADE: Evidence: High; Strength: Strong]
RECOMMENDATION #22: 
Substituting a pharmacologically different drug as a specific 
intervention to mitigate BZRA withdrawal symptoms during gradual 
dose reduction is not routinely recommended. [GRADE: Evidence: 
Moderate; Strength: Strong]
RECOMMENDATION #23: 
Older adults with a BZRA use disorder whose drug use is escalating 
in spite of medical supervision, have failed prior efforts to withdraw 
their BZRA, are at high risk for relapse or harm, and/or suffer from 
significant psychopathology should be considered for referral to a 
specialty addiction or mental health service. [Consensus]
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Rationale
D espite consensus that benzodiazepine receptor agonists (BZRAs) should be avoided whenever possible in older adults (Kuhn-Thiel et al ., 2014; American Geriatrics Society, 2019), clinicians continue to frequently prescribe these medications in 
this patient population . Recent Canadian data suggest high rates of use persist among older adults, especially females, with 18 .7% 
of females reporting past-year use (Statistics Canada, 2016) . There is evidence, however, that the overall rate of use of BZRAs is 
gradually dropping in Canada . Davies et al . (2018) reported that the prescription rate for benzodiazepines among Ontario 
residents aged 65 and over declined from 23 .2% in 1998 to 14 .9% in 2013 . A Quebec study of older adults reported that 9 .5% of 
those taking benzodiazepines met Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for substance dependence 
(Voyer et al ., 2010) .
S trategies to prevent BZRA use disorder include avoiding the initial prescription of BZRAs, particularly if consumption of these agents would place the older adult at high risk for harm, and following good prescribing practices when they are used . 
Informed older patients and well-trained prescribers, supported by a health care system that offers ready access to non-
pharmacological alternatives, are required to achieve these aims .
Minimizing BZRA Use and Preventing  
BZRA Use Disorder 
RECOMMENDATION #1: 
Long-term use of BZRAs (> 4 weeks) in older adults should 
be avoided for most indications because of their minimal 
efficacy and risk of harm. Older adults have increased 
sensitivity to BZRAs and decreased ability to metabolize 
some longer-acting agents, such as diazepam. All BZRAs 
increase the risk of cognitive impairment, delirium, falls, 
fractures, hospitalizations, and motor vehicle crashes. 
Alternative management strategies for insomnia, anxiety 
disorders, and the behavioural and psychological 
symptoms of dementia (BPSD) are recommended.  
[GRADE: Evidence: Moderate; Strength: Strong]
BZRAs are not first-line agents for the treatment of anxiety, 
insomnia, or BPSD in older adults because of their minimal 
efficacy and concerns about adverse effects (el-Guebaly 
et al ., 2010; Vaapio et al ., 2015; Gage, 2016; Jansen et al ., 
2016) . These drugs are included in commonly used lists of 
medications to avoid in older adults (Hamilton et al ., 2011; 
Kuhn-Thiel et al ., 2014; American Geriatrics Society, 2019) .
Age-related changes in pharmacokinetics and 
pharmacodynamics result in a greater risk of adverse 
effects with BZRAs in older adults at doses lower than 
cited as effective (Tamblyn et al ., 2005; Vaapio et al ., 
2015) . Adverse effects include falls, fractures, cognitive 
impairment, delirium, incontinence, respiratory depression, 
and unplanned hospitalization (American Geriatrics 
Society, 2009; Assem-Hilger et al ., 2009; Lin et al ., 2017) . 
BZRAs can also negatively affect driving skills and are 
associated with higher motor vehicle crash rates at all 
ages (Leufkens & Vermeeren, 2009; Kang et al ., 2012) . 
Prescribers need to be aware of how frequently and quickly 
dependency on BZRAs can develop . As many as 15% of regular 
users have been found to be dependent after 4 months and 
50% after 2 years of use, with some sources citing even 
higher rates (el-Guebaly et al ., 2010) . Efforts to reduce 
physiological dependency would include minimizing 
dosages, prescribing only for short periods of time, 
and/or only using intermittently (Ibid) . It should be 
noted that there are a few conditions, such as REM 
sleep disorder, for which longer-term use of a 
BZRA might be appropriate (Aurora et al ., 2010) .
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RECOMMENDATION #2: 
Appropriate first-line non-pharmacological options for the 
treatment of insomnia and anxiety disorders include 
cognitive behaviour therapies (CBTs) provided in various 
formats. [GRADE: Evidence: Moderate; Strength: Strong]
Both the American College of Physicians (2016) and the 
European Sleep Research Society (2017) recommend CBT 
for insomnia (CBTi) as the first-line treatment for insomnia, 
with BZRAs and other sedative-hypnotics reserved for use 
in patients who fail to benefit from CBTi (Qaseem et al ., 
2016; Riemann et al ., 2017) . This recommendation is based 
on the results of numerous randomized controlled trials 
involving a wide range of patients (including older adults 
with multiple comorbidities) and the poor risk/benefit ratio 
of pharmacotherapies for insomnia . Both CBTi provided 
by a therapist (individually or as a group) or using a self-
help approach (e .g ., CBTi-based books, online services, and 
apps) has been shown to be effective . Sleepwell (Sleepwell .
ca, 2018) provides information about and links to self-
help CBTi resources . Simple sleep hygiene approaches can 
be attempted, although the evidence in support of this 
approach is limited and equivocal (Irish et al ., 2015) .
A meta-analysis by Hendricks et al . (2008) showed that CBT 
provided in a group or individually is an effective treatment for 
anxiety (Hendriks et al ., 2008; Ursuliak et al ., 2008; Soyka, 2017) . 
Enhanced CBT modifies the standard approach to CBT to better 
meet the needs of an older population (Mohlman et al ., 2003; 
Cassidy & Rector, 2008; Ursuliak et al ., 2008) and significantly 
improves measures of depression, anxiety, and quality of life in 
depressed and anxious seniors (Ursuliak et al ., 2008) . Exposure 
and response prevention can be used in CBT to reduce 
anxiety symptoms and redress the underlying avoidance 
that perpetuates anxiety disorders (Davis et al ., 2012) .
RECOMMENDATION #3: 
A BZRA should only be considered in the management of 
insomnia or anxiety after failing adequate trials of non-
pharmacological interventions or safer pharmacological 
alternatives OR for short-term bridging until more 
appropriate treatment becomes effective. 
[GRADE: Evidence: Moderate; Strength: Strong]
The most effective approach to minimizing BZRA use 
disorders is avoiding their use . Strategies for this include: 
primary prevention of conditions in which BZRAs are 
often prescribed (e .g ., insomnia, anxiety disorders, and 
depressive disorders); greater use of non-pharmacological 
alternatives; preferential use of recommended first-line 
pharmacological treatments for anxiety and depression; 
and, ongoing education about the risks of BZRA use (Glass 
et al ., 2005; Sithamparanathan et al ., 2012; Gage, 2016) .
Antidepressants (Selective serotonin reuptake inhibitors [SSRIs] 
and Serotonin and norepinephrine reuptake inhibitors [SNRIs]) 
are recommended first-line pharmacotherapy for anxiety and 
depressive disorders in older adults (Katzman et al ., 2014; 
Kok, 2014; Thorlund et al ., 2015) . BZRAs are not recommended 
for these indications other than for short-term use to relieve 
severe anxiety (Qaseem et al ., 2016) . As noted, insomnia 
should not be treated with BZRAs or other sedative-hypnotics 
options unless more effective and safer non-pharmacological 
options have been tried and shown to be ineffective . The 
2017 practice guideline by the American Academy of Sleep 
Medicine for the pharmacological treatment of insomnia 
provides no strong recommendation for any medication 
currently approved or commonly used to treat insomnia in 
the United States (Qaseem et al ., 2016; Riemann et al ., 2017) .
RECOMMENDATION #4: 
An assessment of risk for BZRA use disorder and other 
potential adverse effects from these agents should be 
done prior to prescribing a BZRA. [Consensus]
Awareness of risk factors for developing dependence 
on a BZRA and BZRA use disorder can help avoid 
inappropriate use . Identified risk factors include: older age, 
female gender, dependent personality, and concurrent 
or previous substance use disorder (Gage, 2016) . As the 
dose of BZRA can affect the likelihood of success with 
tapering (more likely if < 10 mg diazepam equivalent/day 
equivalent), use of lower doses might help decrease rates 
of BZRA use disorders overall (J . Brett & Murnion, 2015) .
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RECOMMENDATION #5: 
If a BZRA is being considered, the older adult should be 
informed of both the limited benefits and risks associated 
with use, as well as alternatives, prior to deciding on a 
management plan. [Consensus]
Awareness of the risks of BZRAs is important both for 
patients and prescribers (Cook et al ., 2007; Canham et al ., 
2014) . Patient knowledge has been shown to correlate with 
successful tapering of medications, while the attitudes and 
skills of primary care physicians have an impact on efforts 
to reduce doses among chronic users of BZRAs . Lack of 
awareness of the risks of use can limit efforts to optimize use 
and lead to delayed recognition of use disorder and other 
adverse effects, such as fatigue, falls, and depression . Older 
patients are less likely to recognize dependency or bring 
concerns to their physicians, whose own lack of awareness 
might make it even more difficult to identify the presence 
of a disorder (Kuerbis et al ., 2014) . It is recommended 
that clinicians offer patients education about the risks of 
BZRAs and make greater use of non-pharmacological and 
alternative pharmacological therapies . Physicians often 
describe having limited skills in reducing BZRA dosages or 
knowledge of alternative treatments (Cook et al ., 2007) . 
RECOMMENDATION #6: 
Initiating treatment with a BZRA should be a shared 
decision between the prescriber and the older adult 
(or their substitute decision-maker). There should be 
agreement and understanding on how the BZRA is to be 
used (including planned duration of no more than 2 to 
4 weeks) and monitored. [Consensus]
BZRAs are high-risk medications in older adults . As 
a result, their prescription should follow the same 
principles used with other high-risk medication 
(please see narrative for recommendations #5 and #7) . 
Prescriptions should be limited to 14 to 28 days . 
RECOMMENDATION #7: 
Older adults who are receiving a BZRA should be:
a.  Educated and provided the opportunity to 
discuss the ongoing risks of taking BZRAs. 
[GRADE: Evidence: Moderate; Strength: Strong] 
Awareness among older adults of BZRA risks allows them 
to make informed decisions and may improve outcomes 
(Funk, 2004; Say et al ., 2006; Moreau et al ., 2012; Turner 
& Tannenbaum, 2017) . Pharmacist-led educational 
interventions consisting of a patient brochure about 
the risks of BZRAs and alternatives (Tannenbaum et 
al ., 2014; Martin & Tannenbaum, 2017) coupled with an 
evidence-based pharmaceutical opinion recommending 
deprescription that is communicated to the prescribing 
physician (Martin et al ., 2018) and one-time counselling of 
patients (Salonoja et al ., 2010) have been shown to decrease 
the use of BZRAs in community dwelling older adults . 
b.  Encouraged to only take the BZRA for a short period 
of time (2 to 4 weeks or less) at the minimally effective 
dose. [GRADE: Evidence: Moderate; Strength: Strong] 
BZRA product monographs for the treatment of insomnia 
recommend short treatment durations (i .e ., 2 to 4 weeks or less) . 
When BZRAs are used as a bridging medication for anxiety 
disorders, it may take 4 to 6 weeks for patients to begin to 
respond to the first-line treatment . Longer-term use should only 
be considered in exceptional circumstances (e .g ., end-of-life care) .
c.  Monitored during the course of their prescription for 
evidence of treatment response and effectiveness, 
current and potential adverse effects, concordance 
with the treatment plan, and/or the development of a 
BZRA use disorder. [Consensus] 
As with any medication, the prescribing health care 
practitioners must provide appropriate follow-up 
care . Patients should be monitored for evidence of 
effectiveness and signs of any complications . Drug 
therapy should be stopped if it is not effective or the 
risks of continued use outweigh the benefits .
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d.  Supported in stopping the drug, which may require a 
gradual reduction until discontinued. [GRADE: Evidence: 
Moderate; Strength: Strong] 
See the narratives for recommendations #16 and #17 . 
RECOMMENDATION #8: 
Health care providers and organizations should consider 
implementing interventions to decrease inappropriate use 
of BZRAs in their practice settings. These include 
medication reviews, prescribing feedback, audits and 
alerts, multidisciplinary case conferences, and brief 
educational sessions. Regulators, health authorities, and 
professional organizations should consult with clinical 
leaders and older adults to develop and implement 
policies that aim to minimize inappropriate use of BZRAs. 
[GRADE: Evidence: Low; Strength: Strong]
A variety of strategies to improve prescribing practices, with 
the goal of reducing BZRA use, have been studied . Although 
the effect sizes are variable, relatively modest interventions 
not requiring large financial or human resource commitments 
have been shown to be helpful . Increasing awareness and 
education have been the focus of most interventions, rather 
than structural changes such as formulary restriction . Brief 
interventions, such as lectures about adverse drug effects, 
have also been shown to reduce use (Salonoja et al ., 2010; 
Mugunthan et al ., 2011; Soyka, 2017) . Organizational 
strategies in care facilities that are useful in BZRA reduction 
include pharmacist-led chart audits, medication reviews, 
interdisciplinary care conferences, and educational sessions 
for staff (Westbury et al ., 2010) . Some strategies to improve 
BZRA prescribing practices have also successfully focused on 
optimizing the use of other psychotropic medications, such 
as reducing the use of antipsychotics . (Westbury et al ., 2018) . 
RECOMMENDATION #9: 
Health care institutions, including acute care hospitals 
and long-term care facilities, should implement protocols 
that minimize new prescriptions for BZRAs because of the 
potential for harm and the risk of this leading to 
long-term use following discharge to the community or 
other transitions in care. [GRADE: Evidence: Low; Strength: 
Strong]
Transitions of care are high-risk periods for older adults . BZRAs 
are frequently used during hospital admissions, often with 
the intent of short-term use . However, database studies have 
found that a small but significant percentage of the long-term 
use of BZRAs in the community start during hospitalizations . 
A Canadian study found that 3 .5% of older hospitalized 
patients had a BZRA prescription that lasted beyond the 
hospital stay, with 1 .5% still receiving BZRAs 6 months after 
discharge (Bell et al ., 2007) . Risks for long-term use included 
concurrent alcohol use, intensive care unit (ICU) stay, comorbid 
medical conditions, and use of multiple other medications . 
Choosing Wisely Canada (CWC) is a national voice for reducing 
unnecessary tests and treatments in health care . A Psychiatry 
CWC recommendation is to avoid routine continued use 
of BZRAs that were initiated during an acute care hospital 
admission without a careful review and plan for tapering and 
discontinuing, ideally prior to hospital discharge . Medication 
reconciliation (the systematic and comprehensive review of all 
the medications a patient is taking to ensure that medications 
being added, changed, or discontinued are carefully evaluated) 
is a Required Organizational Practice of Accreditation Canada 
and should be done when older adults are admitted, transferred, 
and discharged from a health care facility (Accreditation Canada 
et al ., 2012) . There are a variety of approaches to medication 
reconciliation . We recommend that it include a comprehensive 
review of the appropriateness of current medications and 
development of a management plan related to ongoing use . 
Such an approach offers opportunities to critically review the 
indications for BZRAs, consider the risk/benefits of continued 
use for individual patients, and optimize BZRA use .
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RECOMMENDATION #10: 
Health care practitioners, older adults, and their families 
should advocate for adequate access and funding of 
effective non-pharmacological alternatives for the 
management of insomnia, anxiety disorders, and BPSD. 
[GRADE: Evidence: Low; Strength: Strong]
There is good evidence that the first-line treatments for most 
patients with these conditions are non-pharmacological . 
Even when pharmacological treatment is indicated, it should 
be used along with non-pharmacological interventions . 
However, there is limited access to and provincial coverage for 
non-pharmacological treatments, especially if not provided 
by a physician . Even when provided by a physician, there 
are often limits placed on the frequency and duration of 
therapy . Advocacy by individuals, seniors’ groups, and national 
organizations and associations can potentially help to change 
rules for the provincial funding of non-pharmacological 
treatments (CMPA, Arya, 2013; 2017) . Individual clinicians 
may suggest to those they care for that they write letters to 
their Member of Parliament (MP) or provincial representative . 
The limitations to access and to funding are unlikely to 
change without effort from providers, those in need of 
care, and the organizations that advocate for them .
RECOMMENDATION #11: 
Clinicians should be aware that BZRAs are prescribed more 
frequently to women and the potential implicit bias that 
may lead to inappropriate use. [GRADE: Evidence: Low; 
Strength: Weak]
Historically, marketing of psychiatric medications has tended 
to emphasize their use by women . Women are more frequently 
portrayed in print advertisements for antidepressants or 
anti-anxiety medications targeted at prescribers (Munce 
et al ., 2004) . The concept of implicit bias (the attitudes or 
stereotypes that affect our understanding, actions, and 
decisions in an unconscious manner) has affected perspectives 
in a variety of fields, including health care . The association 
between gender and use of BZRAs has been shown in 
multiple drug database studies and reports (CIHI, 2018) . 
Implicit bias may be contributing to this greater likelihood 
of BZRA use among women in the management of anxiety 
and insomnia . Clinicians should minimize use of BZRAs 
regardless of the gender of the person being treated but 
should be aware of the higher use among women and the 
potential role of implicit bias in their prescribing practices .
Recognition and 
Assessment of BZRA 
Use Disorder 
C linicians may underestimate the likelihood of substance misuse or a substance use disorder 
among older adults . It is therefore important to conduct 
a comprehensive history of current and past use of 
substances, including BZRAs . Although our Guidelines 
are described in four separate documents, multiple 
substance use is common . A comprehensive assessment is 
recommended when substance use disorder is suspected .
RECOMMENDATION #12: 
All older adults should be asked about current and past 
consumption of substances that might lead to substance 
use disorders, including BZRAs, during periodic health 
examinations, admissions to facilities or services, 
perioperative assessments, when considering the 
prescription of a BZRA, and at transitions in care. 
[Consensus]
Substance use (e .g ., alcohol, BZRAs [and other sedatives, 
hypnotics, or anxiolytics], cannabis, hallucinogens, inhalants, 
opioids, stimulants, tobacco) is common among older 
Canadians (Patten, 2018) but often remains unrecognized 
by their health care providers (Saitz et al ., 1997) . Inquiring 
about current and prior use of these substances in a non-
judgmental, non-ageist manner will normalize conversations 
about them and help determine if use is or was present . 
This information is a necessary first step in the detection of 
substance use disorders and can aid in the assessment of 
presentations where their use may be a contributing factor to 
other medical concerns (e .g ., confusion, falls) . Detection of use 
can also lead to the avoidance of adverse drug interactions 
and provide opportunities for education, counselling, and/
or referral of the older adult to treatment programs . 
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RECOMMENDATION #13: 
Health care practitioners should be aware of and vigilant 
to the symptoms and signs of substance use disorders, 
including BZRA use disorder. Particular attention should 
be paid to this possibility when assessing common 
conditions encountered in older adults, such as falls and 
cognitive impairment. [Consensus] 
Lack of awareness or recognition of BZRA use disorders 
among both older adults and their clinicians is of concern . 
Use of DSM-5 criteria are recommended for the detection 
of a BZRA use disorder (the 11 DSM-5 criteria for BZRA 
use disorder are listed on page 5 above) . The number of 
diagnostic criteria present can be used to gauge the severity 
of the substance use disorder: 2 to 3 indicates mild severity, 
while 4 to 5 would be indicative of moderate severity, and 
6+ would indicate the presence of a severe substance use 
disorder . There are unique challenges (e .g ., higher likelihood 
of impaired cognition interfering with ability to self-monitor, 
sensitivity to BZRAs, changes in activity and role obligations, 
attributing manifestations to other known health issues) in 
the diagnosis of a substance use disorder in an older adult 
using these criteria (Rao & Crome, 2016; Han & Moore, 2018) . 
Another diagnostic system used in some countries is the 
International Classification of Diseases (ICD-10), which 
separates Harmful Use from Dependence . The latter includes 
cravings, tolerance, evidence of withdrawal, difficulties 
controlling use, neglect of alternative pleasures or interests, 
and persisting use despite evidence of harm . The five-
item Severity of Dependence Scale is a recommended 
instrument for the detection of BZRA psychological 
dependency in the community (de las Cuevas et al ., 2000) . 
A single screening question (“How many times in the past 
year have you used an illegal drug or used a prescription 
medication for non-medical reasons?”) was validated for the 
detection of substance use disorders in an American primary 
care setting (Smith et al ., 2010), but is not recommended for 
use in Canada prior to testing in our country . A two-question 
pre-screen (a positive response to either having tried to 
cut down or having used more than intended over the last 
year) has been suggested as a way to detect individuals 
who require a more in-depth assessment for a possible 
substance use disorder (Schonfeld et al ., 2015) . 
RECOMMENDATION #14: 
Assessment of older adults suspected of having a BZRA 
use disorder should include indication, dose, duration, 
features indicative of BZRA use disorder, readiness to 
change, and presence of both medical and psychiatric 
comorbidities, including any other past or current 
substance use or misuse. [Consensus]
The assessment should be done in a nonjudgmental, non-
ageist manner, taking into account the values and experiences 
of the older adult (Royal College of Psychiatrists, 2015) . A 
systematic evaluation of BZRA use as well as the characteristics 
of the older adult, including their environment are required . 
Inquiry about the BZRA would include onset of consumption, 
indication(s) for use, name of agent(s), manner taken (dose, 
route, duration), how BZRA was obtained (including whether 
aberrant drug-taking behaviours are present), pattern of intake 
(e .g ., escalating vs . stable), and use of other substances . 
The presence of substance use disorder criteria, severity of 
the disorder (if present), prior interventions, and readiness 
to change should also be determined . The characteristics 
of the older adult that must be noted include age, gender, 
personal and family psychiatric history (including past history 
of substance use disorders), medical history (including 
potential BZRA adverse effects, such as anterograde 
amnesia, inattention, delirium, disinhibition, sedation, 
motor impairment, imbalance, and falls), other medication 
use (including potential adverse interactions), intake of 
caffeine, and functional status (Griffin et al ., 2013) .
Patient assessment should include vital signs, indications of 
possible withdrawal, focused physical examination including 
balance and gait, and a mental status exam including an 
objective brief assessment of cognition . Living arrangements 
(including stability) and social support, both currently 
and potentially available, should be determined . When 
possible, collateral information should be obtained (J . Brett 
& Murnion, 2015) . The information gathered should then be 
used to construct a treatment plan with the older adult . 
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RECOMMENDATION #15:
a.  Multiple substance use is common and should be 
considered and inquired about in all older adults 
with a BZRA use disorder. [GRADE: Evidence: Moderate; 
Strength: Strong] 
Among U .S . veterans, more than 25% of those with one 
substance use disorder had an additional substance use 
disorder (Bhalla et al ., 2017) . Rounsaville et al . (2003) 
wrote in their review of the topic that, “Substance 
abusing patients who exclusively abuse a single 
substance have become progressively scarce and 
unrepresentative of the general population of substance 
abusers in community and clinical settings” . 
Both population and clinical surveys indicate that the 
majority of those with a current substance use disorder 
are taking multiple psychoactive substances and meet 
current or lifetime criteria for multiple substance use 
disorders . Data from the United States indicate that the 
odds of past‐year multiple substance use disorders are 
greater among males, younger adults, African‐Americans, 
and those with mood, personality, posttraumatic stress, 
or multiple psychiatric disorders (McCabe et al ., 2017) .
b.  Health care practitioners should avoid prescribing 
BZRAs concurrently with opioids whenever possible. 
[GRADE: Evidence: Moderate; Strength: Strong] 
Narcotic overdoses are significantly more likely to occur if 
an opioid is combined with a BZRA (Karaca-Mandic et al ., 
2017; Sun et al ., 2017) . In the United States, benzodiazepines 
are present in more than 30% of overdoses involving 
prescription opioids (Karaca-Mandic et al ., 2017) . There is 
also a higher mortality rate with an opioid overdose if the 
two are combined (Dasgupta et al ., 2016) . The Center for 
Disease Control and Prevention (CDC) 2016 Guideline for 
prescribing opioids for chronic pain recommends avoidance 
of concurrent prescription of opioid pain medication and 
benzodiazepines whenever possible (Dowell et al ., 2016) . 
Canadian guidelines on the management of chronic non-
cancer pain state that opioids and benzodiazepines should 
be prescribed together only rarely (Busse et al ., 2017) .
c.  The combination of a BZRA with alcohol should be 
avoided. [GRADE: Evidence: Low; Strength: Weak] 
Alcohol can potentiate and worsen sedation when combined 
with a variety of medications, including BZRAs . As with opioids, 
there are observational studies that suggest that the 
combination of alcohol and benzodiazepines is common 
among patients who are admitted with overdoses and is 
associated with a higher risk of death (Koski et al ., 2003; Jones 
et al ., 2014; Zanjani et al ., 2016) . 
Management of BZRA 
Use Disorder 
T his section focuses on the management of individuals who have developed a BZRA use disorder . Even without 
evidence of a BZRA use disorder, clinicians will often 
wish to deprescribe BZRAs in older patients because of 
the risk of side effects . Many of the recommendations in 
this section of the document, such as those focusing on 
gradual dose reduction, are also relevant to this group .
RECOMMENDATION #16: 
A person-centred, stepped-care approach to enable the 
gradual withdrawal and discontinuation of BZRAs should 
be used. Clinicians and patients should share in: 
a) planning and applying a gradual dose reduction 
scheme supported by appropriate education of the 
patient; b) identifying and optimizing alternatives to 
manage the underlying health issue(s) that initiated or 
perpetuated the use of BZRAs; c) developing strategies 
to minimize acute withdrawal and managing rebound 
symptoms as needed; and d) establishing a schedule of 
visits for reviewing progress. [GRADE: Evidence: Moderate; 
Strength: Strong]
A stepped care approach to deprescribing BZRAs, starting with 
brief interventions and then progressing to multicomponent 
approaches, was pioneered by Lader and Russel (1993) and 
remains the standard of care (Lingford-Hughes et al ., 2012) . 
The stepped care approach emphasizes patient 
involvement in developing and modifying the treatment 
plan . Jansen and colleagues summarize the importance 
of shared decision-making in reducing inappropriate 
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drug therapy in older adults, highlighting the need to respect 
patient goals and values (Jansen et al ., 2016) . A large study of 
older adult BZRAs users given instructions to reduce use 
coupled with a lecture about risks by a geriatrician revealed a 
sustained decrease in regular use by 35% (Salonoja et al ., 2010) .
Self-efficacy (an individual’s belief in their ability to achieve 
goals) is a predictor of adherence with a tapering protocol 
(Belanger et al ., 2005) . Canadian print and online educational 
resources include the Sleepwell website, deprescribing .org, 
and the Canadian Deprescribing Network . A Canadian guideline 
on deprescribing BZRAs used primarily for insomnia was 
published recently (Pottie et al ., 2018) . 
Gradual dose reduction (GDR) is the central tenet in 
discontinuing long-term BZRA use . A pharmacist working 
together with the older adult and prescriber can assist in the 
development of a practicable dose reduction plan, making 
modifications as necessary . Establishing a plan is required for 
regular meetings to both monitor progress of deprescription 
and assess and manage underlying health issue(s) that may 
have instigated or perpetuated BZRA use . An approach 
to overcoming resistance is important and can include: 
involving the family, explaining that tapering is a therapeutic 
trial that can be halted, and emphasizing that tapering 
often results in the person having better mood, energy, and 
function, with reduced risk of falls and other adverse events .
RECOMMENDATION #17: 
Abrupt discontinuation of a BZRA after intermediate to 
long-term use (> 4 weeks) in individuals with BZRA use 
disorder should be avoided due to the risk of withdrawal 
symptoms, substance dependence reinforcement, 
rebound phenomena, and/or higher likelihood of relapse 
with resumption of BZRA use. [GRADE: Evidence: Moderate; 
Strength: Strong]
BZRA withdrawal is characterized by a constellation of physical, 
emotional, and cognitive symptoms that range in severity . 
They include hypertension, tachycardia, agitation, depressive 
or anxiety symptoms, tremor, headache, and paresthesias . Less 
commonly, they include psychosis, depersonalization, delirium, 
seizures, and rarely death (Hoffman et al ., 2014) . Onset varies 
with the elimination half-life of the BZRA (1 to 2 days for 
short-acting agents and up to several weeks for long-
acting ones) (Naranjo et al ., 1981; Greenblatt et al ., 1983; 
Leslie & Inouye, 2011; White et al ., 2012; Hoffman et al ., 
2014) . A small number of patients may experience a 
protracted withdrawal syndrome lasting months . 
As a result of age-related decreases in drug clearance, 
withdrawal symptoms may be less acute in older adults 
(Schweizer et al ., 1989; Cantopher et al ., 1990), but these 
individuals may be more prone to cognitive effects such as 
confusion (Foy et al ., 1986) . Risk factors for BZRA withdrawal 
include greater daily doses of the BZRA, use of short-acting 
agents, and chronic sustained use . Symptoms of depression 
and anxiety, less education, and certain personality traits 
increase the risk of severe withdrawal symptoms (Rickels et 
al ., 1990; Nelson & Chouinard, 1999) . The greater prevalence 
of cardiovascular disease and cognitive impairment 
among older adults predisposes them to experiencing 
delirium or demand-related cardiovascular ischemia during 
withdrawal, especially in the postoperative setting (Biswas 
et al ., 2005; Brown & Deiner, 2016) . Older adults with BZRA 
use disorders may require increased doses of anaesthetic 
agents for induction (White et al ., 2012; Moran et al ., 2015) .
Supervised GDR is the preferred tapering strategy . The ideal 
rate of tapering has not been established, although initially 
decreasing the dosage by 10% to 25% every 1 to 2 weeks is 
a reasonable strategy for most older adults, though the type 
of BZRA, dosage used, and duration of therapy will influence 
this . With GDR, withdrawal symptoms are usually mild or 
absent (Paquin et al ., 2014; Ng et al ., 2018; Pottie et al ., 2018) . 
Various rates of tapering have been studied but not compared 
head-to-head . During the earlier stages of withdrawal, 
dose reductions are generally better tolerated than in the 
latter stages, when the pace of tapering may have to be 
slowed . It may take up to 6 months to successfully wean 
an older adult off a BZRA (Lader & Russell, 1993; Voshaar 
et al ., 2006; Lingford-Hughes et al ., 2012; RACGP, 2017) .  
Please see Table 1 for suggestions on tapering . Knowing 
the indication for the BZRA may aid in the identification of 
likely relapse symptoms . Inpatient admission should be a 
consideration for patients withdrawing from very high doses . 
Patients who have had a short duration of use or have been 
taking very low dosage of a BZRA may not require tapering .
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Table 1 . Recommended BZRA tapering schedule
DURATION OF USE RECOMMENDED TAPER RATE RECOMMENDED TAPER DURATIONS COMMENTS 
< 2 to 4 weeks N/A N/A Tapering may not be required unless 
there are signs of (or multiple risk 
factors for) withdrawal syndrome
4 weeks to 
6 months
10% to 25% of current BZRA 
dose every 1 to 2 weeks 
(consider slower rate at end)
1 to 3 months Factors to be considered in 
deciding on rate of tapering 
include current BZRA dose, 
half-life of the agent, severity of 
substance use disorder or other 
BZRA adverse effects, emergence 
of withdrawal symptoms, presence 
of polysubstance use, drug 
formulation and ease of dividing/
compounding, and patient 
preference
> 6 months 10% of current BZRA dose 
every 2 to 4 weeks (slower rate 
at end)
3 to 6 months
RECOMMENDATION #18: 
Management of acute BZRA withdrawal symptoms should 
be monitored carefully and can be guided by a validated 
tool [e.g. Benzodiazepine Withdrawal Symptom 
Questionnaire, Clinical Institute Withdrawal Assessment-
Benzodiazepine (CIWA-B)] and managed with 
symptom-driven judicious use of an appropriate BZRA. 
[GRADE: Evidence: Low; Strength: Weak] 
BZRA withdrawal is triggered by an abrupt discontinuation 
or marked dose reduction of a BZRA in an individual 
on chronic therapy . While there are a variety of tools for 
assessing benzodiazepine withdrawal, only the CIWA-B, 
Benzodiazepine Withdrawal Symptom Questionnaire, and 
Physician Withdrawal Checklist have been validated among 
adults (Busto et al ., 1986; Tyrer et al ., 1990; Rickels et al ., 
2008) . While these scales have been used to monitor older 
patients in deprescribing programs and clinical trials, they 
have not been specifically validated among adults at an 
advanced age or those with cognitive impairment . In order to 
manage distressing symptoms during withdrawal, judicious 
use of a BZRA guided by symptoms may be required .
RECOMMENDATION #19: 
Regimens involving multiple BZRAs should be simplified 
and converted to a single BZRA. [Consensus]
The risks (e .g ., adverse drug events, non-adherence, drug 
interactions) of the simultaneous use of multiple medications 
in older people are well documented (Cooper et al ., 2015) . 
Therapeutic duplication (i .e ., concurrent use of more than one 
drug from a class) represents potentially inappropriate 
medication use . The concurrent consumption of multiple 
BZRAs can result in exaggerated pharmacological effects, 
unintended overdosing, and other potential adverse reactions . 
While concurrent use of two or more BZRAs may be intentional, 
it often arises when patients have multiple prescribers and/or 
pharmacies . In an effort to minimize the risk of adverse effects 
and also to set the stage for an attempt to wean the older 
adult off BZRAs, it is recommended that multiple BZRA 
regimens be simplified to the use of a single BZRA . This will 
require a dosage of the BZRA used that is equipotent to the 
sum of the multiple BZRAs that the older adult had been 
taking (Ashton, 2007) . Various BZRA equivalency tables are 
available in print and online, for example: https://www .benzo .
org .uk/bzequiv .htm .
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RECOMMENDATION #20: 
The routine switching of a short half-life BZRA with one 
having a long half-life to aid in withdrawing BZRAs is not 
generally recommended in older adults. Switching may 
have a role in certain situations, such as when withdrawal 
is being hindered by a limited number of available BZRA 
pill strengths or when alprazolam is the agent of 
dependence or misuse. [GRADE: Evidence: Moderate; 
Strength: Strong] 
There is limited evidence to support switching from a short- 
to a long half-life BZRA before beginning GDR (Denis et 
al ., 2006) . It may be useful if reduction of the short half-life 
BZRA causes problematic withdrawal symptoms . Avoidance 
of routine replacement with long half-life BZRA is prudent in 
older adults because they are prone to drug accumulation 
with long half-life agents due to age-related changes in 
pharmacokinetic processes . Alprazolam is considered to 
have some unique properties that increase its misuse 
liability (Ait-Daoud et al ., 2018) . As a result, it should be 
tapered very slowly, and substitution with a longer half-
life BZRA, such as clonazepam could be considered with 
this drug . Advice from a specialty service may be required 
in dealing with alprazolam, especially if it has been used 
at a high dose and/or a prolonged period of time .
RECOMMENDATION #21: 
Psychological interventions such as CBT should be 
considered during efforts to withdraw BZRAs as they can 
improve the older adult’s experiences and increase the 
likelihood of stopping the BZRA. [GRADE: Evidence: High; 
Strength: Strong]
The enhancement of Gradual Dose Reduction (GDR) with 
psychological interventions is among the most studied 
multicomponent interventions to reduce benzodiazepine 
use in older adults . High-quality evidence has emerged with 
the use of CBT in particular . A meta-analysis of adults aged 
50+ in various treatment settings by Gould et al . (2014) found 
odds ratios for not using benzodiazepines at the completion 
of the intervention and then 3 and 12 months afterwards of 
5 .06, 3 .90, and 3 .00, respectively, when GDR was combined 
with psychological interventions(Gould et al ., 2014 .) 
Systematic reviews by Reeve (2017) and Paquin (2014) 
provided similar support . A Cochrane Review (Darker 
et al ., 2015) of mixed-age benzodiazepine users 
reported that GDR plus CBT was more likely to 
result in discontinuation of benzodiazepines at the 
completion of treatment (relative risk [RR] 1 .40) and at 3-month 
follow-up (RR 1 .51) but with unclear longer-term benefits . 
Research to date has focused on benzodiazepines . It is likely 
similar benefits would apply to withdrawal from z-drugs, but 
this requires extrapolation from the available data . There are 
few (if any) potential risks, durable effects beyond the end 
of the intervention, and secondary benefits (i .e ., dealing with 
emotional distress, sleep, quality of life) . Access, feasibility in 
individuals with moderate-to-severe cognitive impairment, 
and the need for a motivated patient may be limiting . 
Further work is needed to better define the specific cognitive 
and/or behavioural elements that are most beneficial . 
RECOMMENDATION #22: 
Substituting a pharmacologically different drug as a 
specific intervention to mitigate BZRA withdrawal 
symptoms during gradual dose reduction is not routinely 
recommended. [GRADE: Evidence: Moderate; Strength: Strong]
Adding a pharmacologically different medication when 
withdrawing a BZRA has been studied in a small number 
of trials involving older adults . Melatonin, trazodone, 
carbamazepine, paroxetine, divalproex, buspirone, and 
progesterone have been examined as agents either prescribed 
on a temporary or permanent basis (Gould et al ., 2014; Paquin 
et al ., 2014; Wright et al ., 2015; Reeve et al ., 2017) . Their 
routine use cannot be recommended because of the lack of 
consistent benefit and the heterogeneity of these studies . 
Other considerations include potential toxicity of replacement 
agents, risks of polypharmacy, and misalignment with the 
desire of most patients to avoid unnecessary medications . 
Gabapentinoids (gabapentin and pregabalin) have been 
considered potentially helpful because they are GABA analogs . 
However, they cannot be recommended, as they have not 
been well-studied in BZRA withdrawal (Fluyau et al ., 2018) . 
These drugs are not approved for the indication of BZRA 
withdrawal and carry their own risk for misuse (Mayor, 2018; 
Peckham et al ., 2018) . 
A recent review (Markota et al ., 2016) advises against the 
routine use of another pharmacological agent to support 
efforts to discontinue BZRAs . The British Association for 
Psychopharmacology (Lingford-Hughes et al ., 2012) likewise 
cautions against routinely using another drug but notes that 
this can be considered for individual patients . The use of 
pharmacologically distinct medications may be appropriate 
when being used for the treatment of an ongoing condition 
that instigated or is perpetuating the use of the BZRA .
19
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
RECOMMENDATION #23: 
Older adults with a BZRA use disorder whose drug use is 
escalating in spite of medical supervision, have failed 
prior efforts to withdraw their BZRA, are at high risk for 
relapse or harm, and/or suffer from significant 
psychopathology should be considered for referral to a 
specialty addiction or mental health service. [Consensus]
Many older adults with BZRA use disorders can be successfully 
treated as outpatients in a primary care setting . Those who 
have failed previous attempts of withdrawal or are at high 
risk of relapse, including individuals with severe concurrent 
psychopathology, should be referred for specialty care (Lader 
& Russell, 1993; Welsh Government, 2011; Paquin et al ., 2014; 
Yokoi et al ., 2014; J . Brett & Murnion, 2015) . The ideal specialty 
program would take a holistic interdisciplinary approach 
consisting of medical, addiction, and psychiatric expertise, with 
access to support from pharmacists, case managers, and peer 
support workers working collectively to translate the treatment 
plan into action . Unfortunately, few centres can offer such a 
comprehensive “one-stop” service, able to address the unique 
needs of older adults . In the treatment of concurrent disorders, 
addiction and mental health conditions should be treated in 
parallel as opposed to sequentially . Strategies such as very 
short dispensing periods or daily witnessed ingestion may be 
helpful for patients who have significant difficulty controlling 
their intake of BZRAs . Individuals withdrawing from high doses 
of BZRAs or multiple substances, those who are physically 
frail, and those who lack community supports should be 
considered for inpatient treatment in a suitable facility .
Ethical Challenges in 
Deprescribing
C linical Practice Guidelines (CPGs) can inform appropriate care but do not, in isolation, define it (College of 
Physicians & Surgeons of Ontario (CPSO, 2017) . Good care 
can deviate from CPGs given the nuances and complexities 
of individual cases . An older adult’s perception of the balance 
between benefits versus risks of BZRA use is dependent 
upon being fully informed of such considerations and 
alternatives by their physician . The older adult’s personal 
values and other factors further delineate the clinician’s 
assessment of whether withdrawal of the BZRA is indicated . 
Proposing that a BZRA be discontinued may be met with 
resistance, particularly when the older adult perceives the 
BZRA to be beneficial . The perception of benefit is likely related 
to the degree to which the older adult was impacted by the 
original target symptoms, as well as the degree to which 
these symptoms improved with the BZRA . The clinician must 
consider the possibility of harm from continued use, which 
would include the development of a substance use disorder 
arising from the BZRA . Although avoiding or discontinuing 
the long-term use of a BZRA is in general the recommended 
course of action for the majority of older adults, it does not 
follow that this is indicated for each individual . Discontinuing 
a medication is an active intervention, the ethics of which 
can be informed by several bioethical models . Shared 
decision-making should incorporate clinical judgment, 
patient values, and lived experience but must also be made 
within the confines of professional standards of practice . 
After considering all perspectives, if the clinician believes that 
the harms of continuing BZRA therapy significantly outweigh 
the benefits, deprescribing should be actively encouraged 
and adopted . Prescribers who are uncomfortable continuing 
to prescribe a BZRA to an older adult do not have a duty 
to do so, as it is ethically indefensible to provide treatment 
against sound medical judgement, though it is emphasized 
that discontinuing a BZRA being used long-term should 
never be done abruptly (Weijer et al ., 1998; Lantos et al ., 
2011; A . Brett & McCullough, 2012; Kapoor et al ., 2018) .
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Future Directions
C oncern about the risks of BZRAs for older adults has grown in recent years . The developers of these 
guidelines hope to inspire prescribers and health care 
team members, as well as older adults and their families, 
to consider, implement, and support alternatives to these 
medications . This document bridges the gap between 
knowledge and practice and is designed to facilitate 
change at personal, institutional, and system levels .
These guideline developers advocate for integration of 
policies and specialized clinical education that supports 
progressive models of care, to empower older adults to 
participate in shared decision-making when the prescribing 
and deprescribing of BZRAs is being considered . It is also 
important to ensure access to clinicians who are able to offer 
non-pharmacological therapies such as CBT and CBTi to 
older adults, in order to both prevent the inappropriate use 
of BZRAs and to aid those who are experiencing symptoms 
of a substance use disorder . We encourage hospitals, other 
health care facilities, community-based agencies, and 
their quality improvement teams to routinely explore 
the impact of care transitions on prescribing patterns . 
The health care system is striving to provide holistic, person-
centred care to older adults with substance use disorders . 
However, more education is required to support primary care 
physicians and other clinicians caring for these individuals . 
Unfortunately, in some regions of Canada, access to 
specialized addiction and/or mental health services for older 
adults is limited or non-existent . To this end, we encourage 
the development of comprehensive, evidence-based, 
interprofessional models of care that support the full scope 
of practice of all team members . It is important to emphasize 
that more research is needed to determine the optimal 
treatment and models of care for older adults with substance 
use disorders (Lehmann & Fingerhood, 2018) . Over time, it 
will be increasingly important to develop systems of care able 
to meet the complex health needs of diverse groups of older 
adults, including the growing number of baby boomers . 
The CCSMH welcomes your feedback and requests both your 
support and active participation in the wide dissemination of 
these important guidelines . 
21
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Accreditation Canada, et al. (2012). Medication reconciliation in Canada: 
Raising the bar – Progress to date and the course ahead. Retrieved 
from https://www.ismp-canada.org/download/MedRec/20121101 
MedRec CanadaENG.pdf
Ait-Daoud, N., et al. (2018). A Review of Alprazolam Use, Misuse, and 
Withdrawal. J Addict Med, 12(1), 4-10. doi:10.1097/
ADM.0000000000000350
American Geriatrics Society. (2009). Pharmacological management of 
persistent pain in older persons. Pain Med, 10(6), 1062-1083. 
doi:10.1111/j.1526-4637.2009.00699.x
American Geriatrics Society. (2019). American Geriatrics Society 2019 
Updated AGS Beers Criteria(R) for Potentially Inappropriate 
Medication Use in Older Adults. J Am Geriatr Soc, 67(4), 674-694. 
doi:10.1111/jgs.15767
American Psychiatric Association. (2013). Diagnostic and statistical 
manual of mental disorders (5th ed.). Arlington, VA: American 
Psychiatric Publishing.
Arya, N. (2013, 2013/10/15/). Advocacy as medical responsibility. 
CMAJ: Canadian Medical Association Journal, 185, 1368.
Ashton, H. (2007, April). Benzodiazepine equivalence table. Retrieved 
from https://www.benzo.org.uk/bzequiv.htm
Assem-Hilger, E., et al. (2009). Benzodiazepine use in the elderly: an 
indicator for inappropriately treated geriatric depression? Int J 
Geriatr Psychiatry, 24(6), 563-569. doi:10.1002/gps.2155
Aurora, R. N., et al. (2010). Best practice guide for the treatment of REM 
sleep behavior disorder (RBD). Journal of clinical sleep medicine : 
JCSM : official publication of the American Academy of Sleep 
Medicine, 6(1), 85-95. 
Belanger, L., et al. (2005). Self-efficacy and compliance with 
benzodiazepine taper in older adults with chronic insomnia. 
Health Psychol, 24(3), 281-287. doi:10.1037/0278-6133.24.3.281
Bell, C. M., et al. (2007). Initiation of benzodiazepines in the elderly 
after hospitalization. J Gen Intern Med, 22(7), 1024-1029. 
doi:10.1007/s11606-007-0194-4
Bhalla, I. P., et al. (2017). Clinical Epidemiology of Single Versus 
Multiple Substance Use Disorders: Polysubstance Use Disorder. 
Med Care, 55 Suppl 9 Suppl 2, S24-s32. doi:10.1097/
mlr.0000000000000731
Biswas, A. K., et al. (2005). Myocardial ischemia as a result of severe 
benzodiazepine and opioid withdrawal. Clin Toxicol (Phila), 43(3), 
207-209. 
Brett, A., & McCullough, L. B. (2012). Addressing requests by patients 
for nonbeneficial interventions. JAMA, 307(2), 149-150. 
doi:10.1001/jama.2011.1999
Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse 
and dependence. Aust Prescr, 38(5), 152-155. 
Brown, C., & Deiner, S. (2016). Perioperative cognitive protection. 
British Journal of Anaesthesia, 117, iii52-iii61. doi:10.1093/bja/
aew361
Busse, et al. (2017). Guideline for opioid therapy and chronic 
noncancer pain. CMAJ, 189(18), E659-E666. doi:10.1503/
cmaj.170363
Busto, U., et al. (1986). Withdrawal reaction after long-term 
therapeutic use of benzodiazepines. N Engl J Med, 315(14), 
854-859. doi:10.1056/nejm198610023151403
Canadian Information for Health Information (CIHI). (2018). Drug use 
among seniors in Canada, 2016. Retrieved from: 
https://www.cihi.ca/sites/default/files/document/drug-use-
among- seniors-2016-en-web.pdf
Canadian Medical Protective Association (CMPA). (2017, May, 2017). 
The physician voice: When advocacy leads to change. Retrieved 
from https://www.cmpa-acpm.ca/en/advice-publications/
browse-articles/2014/the-physician-voice-when-advocacy-leads-
to-change
Canham, S. L., et al. (2014). Perceptions of benzodiazepine 
dependence among women age 65 and older. J Gerontol Soc Work, 
57(8), 872-888. doi:10.1080/01634372.2014.901470
Cantopher, T., et al. (1990). Chronic benzodiazepine dependence. 
A comparative study of abrupt withdrawal under propranolol 
cover versus gradual withdrawal. Br J Psychiatry, 156, 406-411. 
Cassidy, K. L., & Rector, N. A. (2008). The silent geriatric giant: Anxiety 
disorders in late life. Geriatrics and Aging, 11(3), 150-156. 
Cook, J. M., et al. (2007). Older patient perspectives on long-term 
anxiolytic benzodiazepine use and discontinuation: a qualitative 
study. J Gen Intern Med, 22(8), 1094-1100. doi:10.1007/s11606-007-
0205-5
Cooper, J. A., et al. (2015). Interventions to improve the appropriate 
use of polypharmacy in older people: a Cochrane systematic 
review. BMJ Open, 5(12), e009235. doi:10.1136/
bmjopen-2015-009235
Darker, C. D., et al. (2015). Psychosocial interventions for 
benzodiazepine harmful use, abuse or dependence. Cochrane 
Database Syst Rev(5), CD009652. doi:10.1002/14651858.
CD009652.pub2
Dasgupta, N., et al. (2016). Cohort Study of the Impact of 
High-Dose Opioid Analgesics on Overdose Mortality. Pain 
Med, 17(1), 85-98. doi:10.1111/pme.12907
Davis, T., et al. (2012). Intensive One-Session Treatment of 
Specific Phobias.
References
22
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
de las Cuevas, C., et al. (2000). The Severity of Dependence Scale (SDS) 
as screening test for benzodiazepine dependence: SDS validation 
study. Addiction, 95(2), 245-250. 
Denis, C., et al. (2006). Pharmacological interventions for 
benzodiazepine mono-dependence management in outpatient 
settings. Cochrane Database Syst Rev(3), Cd005194. 
doi:10.1002/14651858.CD005194.pub2
Dowell, D., et al. (2016). CDC Guideline for Prescribing Opioids for 
Chronic Pain – United States, 2016. MMWR Recomm Rep, 65(1), 
1-49. doi:10.15585/mmwr.rr6501e1
el-Guebaly, N., et al. (2010). Are there guidelines for the responsible 
prescription of benzodiazepines? Can J Psychiatry, 55(11), 709-714. 
doi:10.1177/070674371005501104
Fluyau, D., et al. (2018). Challenges of the pharmacological 
management of benzodiazepine withdrawal, dependence, and 
discontinuation. Ther Adv Psychopharmacol, 8(5), 147-168. 
doi:10.1177/2045125317753340
Foy, A., et al. (1986). Confusion after admission to hospital in elderly 
patients using benzodiazepines. Br Med J (Clin Res Ed), 293(6554), 
1072. 
Funk, L. M. (2004). Who wants to be involved? Decision-making 
preferences among residents of long-term care facilities. Can J 
Aging, 23(1), 47-58. 
Gage, L. (2016). Anxiety disorders in older adults. In M. J. Rapoport, D. 
Seitz, A. Wiens, & E. Lilly (Eds.), Geriatric Psychiatry Review and Exam 
Preparation Guide: A Case-Based Approach (pp. 150-163). Toronto, 
ON: University of Toronto Press.
Glass, J., et al. (2005). Sedative hypnotics in older people with 
insomnia: meta-analysis of risks and benefits. BMJ, 331(7526), 
1169. doi:10.1136/bmj.38623.768588.47
Gould, R. L., et al. (2014). Interventions for reducing benzodiazepine 
use in older people: meta-analysis of randomised controlled trials. 
Br J Psychiatry, 204(2), 98-107. doi:10.1192/bjp.bp.113.126003
Greenblatt, D. J., et al. (1983). Reduced clearance of triazolam in old 
age: relation to antipyrine oxidizing capacity. British Journal of 
Clinical Pharmacology, 15(3), 303-309. 
Griffin, C. E., 3rd, et al. (2013). Benzodiazepine pharmacology and 
central nervous system-mediated effects. Ochsner J, 13(2), 
214-223. 
Guyatt, G. H., et al. (2008). GRADE: An emerging consensus on 
rating quality of evidence and strength of recommendations. 
BMJ, 336(7650), 924-926. doi:10.1136/bmj.39489.470347.AD
Hamilton, H., et al. (2011). Potentially inappropriate medications 
defined by STOPP criteria and the risk of adverse drug events in 
older hospitalized patients. Arch Intern Med, 171(11), 1013-1019. 
doi:10.1001/archinternmed.2011.215
Han, B. H., & Moore, A. A. (2018). Prevention and Screening of 
Unhealthy Substance Use by Older Adults. Clin Geriatr Med, 34(1), 
117-129. doi:10.1016/j.cger.2017.08.005
Hendriks, G. J., et al. (2008). Cognitive-behavioural therapy for late-life 
anxiety disorders: a systematic review and meta-analysis. Acta 
Psychiatr Scand, 117(6), 403-411. 
doi:10.1111/j.1600-0447.2008.01190.x
Hoffman, R., et al. (2014). Goldfrank’s Toxicologic Emergencies, Tenth 
Edition. New York, NY: McGraw-Hill Education.
Irish, L. A., et al. (2015). The role of sleep hygiene in promoting public 
health: A review of empirical evidence. Sleep Med Rev, 22, 23-36. 
doi:10.1016/j.smrv.2014.10.001
Jansen, J., et al. (2016). Too much medicine in older people? 
Deprescribing through shared decision making. BMJ, 353, i2893. 
doi:10.1136/bmj.i2893
Jones, C. M., et al. (2014). Alcohol involvement in opioid pain reliever 
and benzodiazepine drug abuse-related emergency department 
visits and drug-related deaths – United States, 2010. MMWR Morb 
Mortal Wkly Rep, 63(40), 881-885. 
Kang, D. Y., et al. (2012). Zolpidem use and risk of fracture in elderly 
insomnia patients. J Prev Med Public Health, 45(4), 219-226. 
doi:10.3961/jpmph.2012.45.4.219
Kapoor, A., et al. (2018). Polypharmacy, the Good Prescribing 
Continuum, and the Ethics of Deprescribing. Public Policy & Aging 
Report, 28(4), 108-112. doi:10.1093/ppar/pry033
Karaca-Mandic, P., et al. (2017). The growing problem of co-treatment 
with opioids and benzodiazepines. BMJ, 356, j1224. doi:10.1136/
bmj.j1224
Katzman, M. A., et al. (2014). Canadian clinical practice guidelines for 
the management of anxiety, posttraumatic stress and obsessive-
compulsive disorders. BMC Psychiatry, 14 Suppl 1, S1. 
doi:10.1186/1471-244X-14-S1-S1
Kok, R. M. (2014). Treatment of alcohol use disorders in the elderly: an 
overview of RCTs. Int Psychogeriatr, 26(11), 1767-1770. doi:10.1017/
S1041610214001781
Koski, A., et al. (2003). Interaction of alcohol and drugs in fatal 
poisonings. Hum Exp Toxicol, 22(5), 281-287. 
doi:10.1191/0960327103ht324oa
Kuerbis, A., et al. (2014). Substance Abuse Among Older Adults. Clinics 
in Geriatric Medicine, 30(3), 629-654. doi:10.1016/j.cger.2014.04.008
23
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Kuhn-Thiel, A. M., et al. (2014). Consensus validation of the FORTA (Fit 
fOR The Aged) List: a clinical tool for increasing the appropriateness 
of pharmacotherapy in the elderly. Drugs Aging, 31(2), 131-140. 
doi:10.1007/s40266-013-0146-0
Lader, M., & Russell, J. (1993). Guidelines for the prevention and 
treatment of benzodiazepine dependence: summary of a report 
from the Mental Health Foundation. Addiction, 88(12), 1707-1708. 
Lantos, J., et al. (2011). Clinician integrity and limits to patient 
autonomy. JAMA, 305(5), 495-499. doi:10.1001/jama.2011.32
Lehmann, S. W., & Fingerhood, M. (2018). Substance-Use Disorders in 
Later Life. N Engl J Med, 379(24), 2351-2360. doi:10.1056/
NEJMra1805981
Leslie, D. L., & Inouye, S. K. (2011). The importance of delirium: 
economic and societal costs. J Am Geriatr Soc, 59 Suppl 2, S241-
243. doi:10.1111/j.1532-5415.2011.03671.x
Leufkens, T. R., & Vermeeren, A. (2009). Highway driving in the elderly 
the morning after bedtime use of hypnotics: a comparison 
between temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin 
Psychopharmacol, 29(5), 432-438. doi:10.1097/
JCP.0b013e3181b57b43
Lin, C. W., et al. (2017). Potentially high-risk medication categories and 
unplanned hospitalizations: a case-time-control study. Sci Rep, 7, 
41035. doi:10.1038/srep41035
Lingford-Hughes, A. R., et al. (2012). BAP updated guidelines: 
evidence-based guidelines for the pharmacological management 
of substance abuse, harmful use, addiction and comorbidity: 
recommendations from BAP. J Psychopharmacol, 26(7), 899-952. 
doi:10.1177/0269881112444324
Markota, M., et al. (2016). Benzodiazepine Use in Older Adults: 
Dangers, Management, and Alternative Therapies. Mayo Clin Proc, 
91(11), 1632-1639. doi:10.1016/j.mayocp.2016.07.024
Martin, P., & Tannenbaum, C. (2017). Use of the EMPOWER brochure to 
deprescribe sedative-hypnotic drugs in older adults with mild 
cognitive impairment. BMC Geriatr, 17(1), 37. doi:10.1186/
s12877-017-0432-5
Mayor, S. (2018). Pregabalin and gabapentin become controlled drugs 
to cut deaths from misuse. BMJ, 363, k4364. doi:10.1136/bmj.
k4364
McCabe, S. E., et al. (2017). Multiple DSM-5 substance use disorders: 
A national study of US adults. Hum Psychopharmacol, 32(5). 
doi:10.1002/hup.2625
Mohlman, J., et al. (2003). Standard and Enhanced Cognitive–Behavior 
Therapy for Late-Life Generalized Anxiety Disorder: Two Pilot 
Investigations. The American Journal of Geriatric Psychiatry, 11(1), 
24-32. doi:10.1097/00019442-200301000-00005
Moran, S., et al. (2015). Perioperative Management in the Patient with 
Substance Abuse. Surgical Clinics, 95(2), 417-428. doi:10.1016/j.
suc.2014.11.001
Moreau, A., et al. (2012). What perceptions do patients have of 
decision making (DM)? Toward an integrative patient-centered 
care model. A qualitative study using focus-group interviews. 
Patient Educ Couns, 87(2), 206-211. doi:10.1016/j.pec.2011.08.010
Mugunthan, K., et al. (2011). Minimal interventions to decrease 
long-term use of benzodiazepines in primary care: a systematic 
review and meta-analysis. Br J Gen Pract, 61(590), e573-578. 
doi:10.3399/bjgp11X 593857
Munce, S. E., et al. (2004). Who is portrayed in psychotropic drug 
advertisements? J Nerv Ment Dis, 192(4), 284-288. 
Naranjo, C. A., et al. (1981). A method for estimating the probability of 
adverse drug reactions. Clinical Pharmacology & Therapeutics, 30(2), 
239-245. doi:10.1038/clpt.1981.154
Nelson, J., & Chouinard, G. (1999). Guidelines for the clinical use of 
benzodiazepines: pharmacokinetics, dependency, rebound and 
withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin 
Pharmacol, 6(2), 69-83. 
Ng, B. J., et al. (2018). Deprescribing Benzodiazepines in Older Patients: 
Impact of Interventions Targeting Physicians, Pharmacists, and 
Patients. Drugs Aging, 35(6), 493-521. doi:10.1007/s40266-018-
0544-4
Paquin, A. M., et al. (2014). Risk versus risk: a review of benzodiazepine 
reduction in older adults. Expert Opin Drug Saf, 13(7), 919-934. doi:
10.1517/14740338.2014.925444
Patten. (2018). Epidemiology of Psychoactive Substance Use Among 
Older Adults. In: Substance use in Canada: improving quality of life: 
substance use and aging. Retrieved from: https://www.ccsa.ca/
sites/default/files/2019-04/CCSA-Substance-Use-and-Aging-
Report-2018-en.pdf
Peckham, A. M., et al. (2018). Gabapentin for Off-Label Use: Evidence-
Based or Cause for Concern? Substance abuse : research and 
treatment, 12, 1178221818801311-1178221818801311. 
doi:10.1177/1178221818801311
Pottie, K., et al. (2018). Deprescribing benzodiazepine receptor 
agonists: Evidence-based clinical practice guideline. Can Fam 
Physician, 64(5), 339-351. 
Qaseem, A., et al. (2016). Management of Chronic Insomnia 
Disorder in Adults: A Clinical Practice Guideline From the 
American College of Physicians. Ann Intern Med, 165(2), 
125-133. doi:10.7326/m15-2175
24
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Rao, R., & Crome, I. (2016). Assessment in the older patient In M. A. 
Sullivan & F. R. Levin (Eds.), Addiction in the Older Patient (pp. 
173-209). Oxford, UK: Oxford University Press.
Reeve, E., et al. (2017). A systematic review of interventions to 
deprescribe benzodiazepines and other hypnotics among older 
people. Eur J Clin Pharmacol, 73(8), 927-935. doi:10.1007/s00228-
017-2257-8
Rickels, K., et al. (2008). Physician Withdrawal Checklist (PWC-20). J Clin 
Psychopharmacol, 28(4), 447-451. doi:10.1097/
JCP.0b013e31817efbac
Rickels, K., et al. (1990). Long-term therapeutic use of 
benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen 
Psychiatry, 47(10), 899-907. 
Riemann, D., et al. (2017). European guideline for the diagnosis and 
treatment of insomnia. J Sleep Res, 26(6), 675-700. doi:10.1111/
jsr.12594
Rounsaville, B. J., et al. (2003). Single versus multiple drug focus in 
substance abuse clinical trials research. Drug and Alcohol 
Dependence, 70(2), 117-125. 
Royal Australian College of General Practitioners (RACGP). (2017). 
Prescribing drugs of dependence in general practice – Part C. 
Retrieved from: https://www.racgp.org.au/download/Documents/
Guidelines/Opioid/Opioid-Guide-Summary.PDF
Saitz, R., et al. (1997). Physician unawareness of serious substance 
abuse. Am J Drug Alcohol Abuse, 23(3), 343-354. 
Salonoja, M., et al. (2010). One-time counselling decreases the use of 
benzodiazepines and related drugs among community-dwelling 
older persons. Age Ageing, 39(3), 313-319. doi:10.1093/ageing/
afp255
Say, R., et al. (2006). Patients’ preference for involvement in medical 
decision making: a narrative review. Patient Educ Couns, 60(2), 
102-114. doi:10.1016/j.pec.2005.02.003
Schonfeld, L., et al. (2015). Screening, Brief Intervention, and Referral 
to Treatment for Older Adults With Substance Misuse. Am J Public 
Health, 105(1), 205-211. doi:10.2105/AJPH.2013.301859
Schweizer, E., et al. (1989). Benzodiazepine dependence and 
withdrawal in elderly patients. Am J Psychiatry, 146(4), 529-531. 
doi:10.1176/ajp.146.4.529
Sithamparanathan, K., et al. (2012). Adverse effects of benzodiazepine 
use in elderly people: A meta-analysis (Vol. 7).
Sleepwell. Retrieved from https://mysleepwell.ca/cbti/ 
May 29th 2019
Smith, P. C., et al. (2010). A single-question screening test for 
drug use in primary care. Arch Intern Med, 170(13), 
1155-1160. doi:10.1001/archinternmed.2010.140
Soyka, M. (2017). Treatment of Benzodiazepine Dependence. N Engl J 
Med, 376(12), 1147-1157. doi:10.1056/NEJMra1611832
Statistics Canada. (2016). Canadian Tobacco Alcohol and Drugs (CTADS): 
2015 summary. Retrieved from: https://www.canada.ca/en/
health-canada/services/canadian-tobacco-alcohol-drugs-
survey/2015-summary.html
Sun, E. C., et al. (2017). Association between concurrent use of 
prescription opioids and benzodiazepines and overdose: 
retrospective analysis. BMJ, 356, j760. doi:10.1136/bmj.j760
Tamblyn, R., et al. (2005). A 5-year prospective assessment of the risk 
associated with individual benzodiazepines and doses in new 
elderly users. J Am Geriatr Soc, 53(2), 233-241. 
doi:10.1111/j.1532-5415.2005. 53108.x
Tannenbaum, C., et al. (2014). Reduction of inappropriate 
benzodiazepine prescriptions among older adults through direct 
patient education: the EMPOWER cluster randomized trial. JAMA 
Intern Med, 174(6), 890-898. doi:10.1001/jamainternmed.2014.949
The College of Physicians and Surgeons of Ontario (CPSO). (2017). 
Prescribing drugs. Retrieved from: https://www.cpso.on.ca/
Policies-Publications/Policy/Prescribing-Drugs
Thorlund, K., et al. (2015). Comparative efficacy and safety of selective 
serotonin reuptake inhibitors and serotonin-norepinephrine 
reuptake inhibitors in older adults: a network meta-analysis. J Am 
Geriatr Soc, 63(5), 1002-1009. doi:10.1111/jgs.13395
Turner, J. P., & Tannenbaum, C. (2017). Older Adults’ Awareness of 
Deprescribing: A Population-Based Survey. J Am Geriatr Soc, 65(12), 
2691-2696. doi:10.1111/jgs.15079
Tyrer, P., et al. (1990). The Benzodiazepine Withdrawal Symptom 
Questionnaire. J Affect Disord, 19(1), 53-61. 
Ursuliak, Z., et al. (2008). An observational study of the effectiveness of 
group cognitive behaviour therapy for late-life depressive and anxiety 
disorders (Vol. 11).
Vaapio, S., et al. (2015). Symptoms Associated with Long-term 
Benzodiazepine Use in Elderly Individuals Aged 65 Years and Older: 
A Longitudinal Descriptive Study. International Journal of 
Gerontology, 9(1), 34-39. doi:10.1016/j.ijge.2014.03.009
Voshaar, R. C., et al. (2006). Predictors of long-term benzodiazepine 
abstinence in participants of a randomized controlled 
benzodiazepine withdrawal program. Can J Psychiatry, 51(7), 
445-452. doi:10.1177/070674370605100706
Voyer, P., et al. (2010). The Prevalence of Benzodiazepine Dependence 
among Community-Dwelling Older Adult Users in Quebec 
According to Typical and Atypical Criteria. Canadian Journal on 
Aging / La Revue canadienne du vieillissement, 29(02), 205-213. 
doi:10.1017/s0714980810000115
25
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
Weijer, C., et al. (1998). Bioethics for clinicians: 16. Dealing with 
demands for inappropriate treatment. CMAJ, 159(7), 817-821. 
Welsh Government. (2011). Substance Misuse Treatment Framework 
(SMTF): Guidance for evidence-based community prescribing in the 
treatment of Substance Misuse. Retrieved from https://gweddill.
gov.wales/docs/dsjlg/publications/
commsafety/110628prescribingen.pdf
Westbury, J., et al. (2018). RedUSe: reducing antipsychotic and 
benzodiazepine prescribing in residential aged care facilities. 
Med J Aust, 208(9), 398-403. 
Westbury, J., et al. (2010). An effective approach to decrease 
antipsychotic and benzodiazepine use in nursing homes: the 
RedUSe project. Int Psychogeriatr, 22(1), 26-36. doi:10.1017/
S1041610209991128
White, P. F., et al. (2012). Perioperative care for the older outpatient 
undergoing ambulatory surgery. Anesth Analg, 114(6), 1190-1215. 
doi:10.1213/ANE.0b013e31824f19b8
Wright, A., et al. (2015). The Effect of Melatonin on Benzodiazepine 
Discontinuation and Sleep Quality in Adults Attempting to 
Discontinue Benzodiazepines: A Systematic Review and Meta-
Analysis. Drugs Aging, 32(12), 1009-1018. doi:10.1007/s40266-015-
0322-5
Yokoi, Y., et al. (2014). Benzodiazepine discontinuation and patient 
outcome in a chronic geriatric medical/psychiatric unit: a 
retrospective chart review. Geriatr Gerontol Int, 14(2), 388-394. 
doi:10.1111/ggi.12113
Zanjani, F., et al. (2016). Concurrent alcohol and medication poisoning 
hospital admissions among older rural and urban residents. Am J 
Drug Alcohol Abuse, 42(4), 422-430. doi:10.3109/00952990.2016.1
154966
Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults
ccsmh.ca
© Canadian Coalition for Seniors’ Mental Health (2019)
